Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. - Wikidata - awgldk - TriplyDB

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.

http://www.wikidata.org/entity/Q33180244

about

Atypical antipsychotics for disruptive behaviour disorders in children and youths Antiepileptics for aggression and associated impulsivity Contemporary assessment and pharmacotherapy of Tourette syndrome Pharmacotherapy of aggression in children and adolescents: efficacy and effect size Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review.The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-a Disruptive mood dysregulation disorder: a new diagnostic approach to chronic irritability in youth Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder Reward processing in autism: a thematic series.Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders.Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths.Neuropsychiatry of aggression.Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD Pharmacotherapy and postdischarge outcomes of child inpatients admitted for aggressive behavior Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder Marijuana withdrawal in humans: effects of oral THC or divalproex.Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.Emotion dysregulation in attention deficit hyperactivity disorder Valproate.The "younger-sibling-at-risk design": a pilot study of adolescents with ADHD and an older sibling with substance use disorder Medication strategies in childhood aggression: a review.The treatment of severe child aggression (TOSCA) study: Design challenges.Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders.Divalproex sodium in the treatment of pediatric psychiatric disorders.Aggression and disruptive behavior disorders in children and adolescents.Neural Mechanisms of Cognitive-Behavioral Therapy for Aggression in Children and Adolescents: Design of a Randomized Controlled Trial Within the National Institute for Mental Health Research Domain Criteria Construct of Frustrative Non-Reward.Spectrum of effectiveness of valproate in neuropsychiatry.Pharmacological treatment of pathologic aggression in children.Use of dronabinol for cannabis dependence: two case reports and review.Comorbidity in pediatric bipolar disorder Recommendations for pharmacological management of inpatient aggression in children and adolescents.Pharmacological management of acute and persistent aggression in forensic psychiatry settings.The appropriateness of treating psychopathic disorders.Atypical antipsychotics for disruptive behaviour disorders in children and youths.Pharmacotherapy of conduct disorder: Challenges, options and future directions.Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.The treatment of bipolar patients with elevated impulsivity and suicide risk.

P2860

Q24200361-32E7A102-1A7F-406E-81A8-A29D45AF5DC4 Q24239975-29D1AE41-EB38-4652-96C0-C1E825DAB709 Q24607941-5AF67D8D-A2D5-4F9B-A363-AFF8ED75BB74 Q24648097-9440C9B6-3C68-4599-8949-711957B5B594 Q24810652-B556FB12-16B2-4515-9E51-EF4BD7A859EC Q26849779-1C25A6A5-154C-44B8-85BC-547D8907AC41 Q27009447-D6B612D4-04C2-4416-B885-CE3B45C396D7 Q28260681-35CDE642-CE25-4F66-BD60-FA3DAF0519E4 Q30462673-327133A5-0076-4D86-AF4B-FEE91D820FF6 Q33411020-2624E1A2-4B61-4A2C-9CA1-3E12FEFA2EF5 Q33664736-89D1F115-E7FF-4021-B89B-161D01B7B13A Q34131298-F8CB6A78-4B5B-42E9-909C-CF35ABCCFAF5 Q34152823-097FBC60-3658-4E3E-993C-EF7EB7048844 Q34155826-AE467C19-60F4-4DCC-BC21-31A42EDF0B50 Q34205490-1BF9632C-8A70-4045-AA4F-17B907B860B1 Q34205524-0A35BBBE-A11B-4E41-BEF4-BE19E808F390 Q34492314-6F9CA3B3-ED81-4A0A-8508-5EC8F54400FA Q34542579-6769843D-3ABD-44A5-8DBD-567AA07EACE3 Q34589479-B25B22D9-676B-4544-B0C0-13C5DF280603 Q34803697-6EDB65EA-C1A7-46A8-B3CB-EE94908EFE4E Q35142736-8263DF47-E451-47B6-BE29-135A05087E8E Q35160280-9E625EF3-99D2-4AB6-B604-7152AA596322 Q35190427-879FD4F0-C518-4006-B5E0-68E2EFE83FF0 Q35595839-73BD5F2F-49A5-4E79-B807-B228BEA7C66E Q35625906-F71F81EA-EB0D-4FC0-A6CD-159710D8F975 Q35939596-24D9843C-69AF-4945-B457-1FA2AF4308B2 Q36106793-E2E2FA7F-D636-4C01-B907-20F844852D99 Q36107152-C6923961-60C8-4F94-92A5-8F7A59C48E72 Q36654452-F7EC2E4C-399A-469E-A75B-4663FD898B27 Q36691749-2A39741C-D250-4999-B8E2-8E77BDAFBBB7 Q37127437-12C6E9E7-B370-4C34-8C7A-245A6FDBAAD2 Q37130288-0C519AFF-A71B-4388-9032-5F3B076DDEDD Q37134087-FE67466D-DE54-4A73-9994-69BDBFE871D5 Q37726988-F2374AE9-AA31-4A70-95F3-C1B079DD0D12 Q37963568-21166AE1-829C-4134-80D5-B517438780C0 Q38439581-344D800A-2FAE-4F30-9E06-1BB334072C99 Q38632745-F19C5FC1-EF9D-4869-A6D2-C70EF4F26603 Q38839950-13BF2665-051F-4950-A3E3-2623C3526C2F Q39208385-8C522AB3-A1D3-43F0-A782-CC43C71E537B Q41431544-29C8BF18-C960-4A32-8193-9E2698F228F9

P2860

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.

http://www.wikidata.org/entity/Q33180244

description

2000 nî lūn-bûn

@nan

2000 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Divalproex treatment for youth ...... o-controlled crossover design.

@ast

Divalproex treatment for youth ...... o-controlled crossover design.

@en

type

label

Divalproex treatment for youth ...... o-controlled crossover design.

@ast

Divalproex treatment for youth ...... o-controlled crossover design.

@en

prefLabel

Divalproex treatment for youth ...... o-controlled crossover design.

@ast

Divalproex treatment for youth ...... o-controlled crossover design.

@en

P1433

Q33180244-564F46BF-D723-4F65-9DAB-86C51E290D60

P1476

Q33180244-9B877A40-C457-4C5A-8AE5-F2283525839E

P2093

Q33180244-02C60255-9CFA-4814-95A7-FC06DD94F1A3

Q33180244-6BA37B88-208C-427B-A4B8-05A2FEF771D2

Q33180244-6D0F9A8B-C9B5-40F5-9EFB-1C57836F8959

Q33180244-72770B99-8DF7-4356-B949-F2DC1FF325D2

Q33180244-7F06CAE7-8F2F-4068-9A8B-634BA4A4994C

Q33180244-AF98F8A4-0EB9-40C1-8DF0-EE0F7BA87090

Q33180244-C1915550-EAC3-453C-AFFD-EDCC4D8317F3

Q33180244-F51DF0A6-0BC6-4CDE-9C60-C7FC833BBC37

P304

Q33180244-F84898CE-2C52-48D1-B610-170886D958BF

P31

Q33180244-430B9FAB-DE00-4C46-B5E2-F82B93DDAF4B

P356

Q33180244-4D30B2D1-A10C-4325-8FEB-D23882B42C49

P407

Q33180244-D393DB78-6DF0-41F4-A1E7-2ED360912B18

P433

Q33180244-2102A7C2-3A4A-4A08-BBBD-8D3624485AF6

P478

Q33180244-D8FF52F5-7694-4BC3-8A9E-78D544E5D3F2

P577

Q33180244-325934EF-655B-4A04-9531-5F11EF6E643A

P698

Q33180244-9CECB01C-ABDF-4ADB-8AB9-BBF778A56627

P921

Q33180244-A11F9CF8-245D-4EE9-9AFA-D44E12C65E35

P356

APPI.AJP.157.5.818

P1433

American Journal of Psychiatry

P1476

Divalproex treatment for youth ...... o-controlled crossover design.

@en

P2093

Daniel W

http://www.w3.org/2001/XMLSchema#string

Donovan SJ

http://www.w3.org/2001/XMLSchema#string

Klein DF

http://www.w3.org/2001/XMLSchema#string

Nunes EV

http://www.w3.org/2001/XMLSchema#string

Parides M

http://www.w3.org/2001/XMLSchema#string

Quitkin FM

http://www.w3.org/2001/XMLSchema#string

Stewart JW

http://www.w3.org/2001/XMLSchema#string

Susser E

http://www.w3.org/2001/XMLSchema#string

P304

818-820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/APPI.AJP.157.5.818

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

157

http://www.w3.org/2001/XMLSchema#string

P577

2000-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10784478

http://www.w3.org/2001/XMLSchema#string

P921